Advancing a class on top of statins
Investors & Media

Investor Overview

Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease. Dyslipidemia is generally characterized by an elevation of low-density lipoprotein cholesterol (LDL-C), or bad cholesterol, triglycerides, or fat in the blood, or both... More >>

NASDAQ | GEMP (Common Stock)

$9.52

 0.20 (2.15%)

High$9.83
Low$9.37
Volume48,886
Market Cap$99,042,102

10/23/17  4:00 p.m. ET

Data provided by Nasdaq. Minimum 15 minutes delayed.
Stock chart for: GEMP.O.  Currently trading at $9.52 with a 52 week high of $21.59 and a 52 week low of $7.20.

Positive Gemcabene Results in Proof-of-Concept Preclinical NASH Study Presented at The Liver Meeting® 2017

10/23/17

Read More

Gemphire to Present New COBALT-1 Clinical Data at the 2017 FH Global Summit

09/25/17

Read More

Gemphire Announces Plans to Advance Gemcabene into Phase 3 Clinical Development

09/19/17

Read More


There are currently no events scheduled.